Birth control discussions at the clinical level are almost entirely efficacy conversations. Failure rates. How to take it correctly. What to do if you miss a dose. The broader picture. What the method contains, what it does to your tissue, what it does to the tissue of your partner, what it does to your hormonal ecology over months and years: is not part of the standard appointment.

This page covers what is in each major contraceptive method, what the documented downstream effects are, and where safer options exist. It is not an argument against contraception. It is an argument for genuine informed consent.

It also covers something almost never addressed: the effects on the male partner. The assumption embedded in most birth control discourse is that the chemicals involved are a women's health concern. Several of them are not.

The overwhelming majority of pre-lubricated condoms sold in the United States are coated with nonoxynol-9 (N-9), both on the inner surface (which contacts the penis) and on the outer surface (which contacts the vagina). N-9 is listed on packaging as a spermicide. What is not listed: N-9 is a nonionic surfactant, a detergent, that destroys sperm by disrupting lipid membranes. It does not discriminate between sperm membranes and epithelial cell membranes.

In 2002, the FDA removed N-9's "safe and effective" labeling for STI/HIV prevention. The WHO issued guidance the same year stating that N-9 should NOT be used for HIV protection, because frequent use increases HIV transmission risk by disrupting the vaginal and rectal epithelial barrier.

The mechanism: N-9 causes microabrasions and epithelial disruption in vaginal, cervical, and rectal tissue. The same tissue that is supposed to serve as a barrier becomes more permeable. In clinical trials of N-9 used for STI prevention, women in the N-9 arm had higher rates of HIV acquisition than controls. (Van Damme L et al., New England Journal of Medicine, 2002)

A healthy vaginal microbiome is dominated by Lactobacillus species that maintain pH between 3.8 and 4.5, produce hydrogen peroxide and bacteriocins, and serve as the primary defense against BV, yeast overgrowth, and STI acquisition. N-9 is not selective. It destroys Lactobacillus. Multiple studies confirm that N-9 use significantly reduces Lactobacillus colonization and raises vaginal pH: creating precisely the conditions associated with bacterial vaginosis, recurrent yeast infections, and increased STI susceptibility.

This means a condom coated with N-9, sold as a protective device, is simultaneously disrupting the body's own protective ecosystem. A woman experiencing recurrent BV or yeast infections who uses N-9-coated condoms has never been asked about this at a clinical visit. The N-9 is on the packaging, in very small text, typically under "lubricant ingredients" rather than "spermicide", and most people never read it.

The inner surface of a pre-lubricated condom is in direct contact with penile skin and the urethral meatus. The urethral mucosa is permeable tissue, similar in its vulnerability to the vaginal and cervical tissue that N-9 is documented to disrupt. Repeated exposure of urethral epithelium to a membrane-disrupting detergent is not a concept that has been studied in depth, because the question has not been prioritized. But the mechanism for harm is not different from the vaginal side.

Lubricant chemicals in conventional condoms: parabens (antimicrobial preservatives), glycerin (sugar alcohol that feeds yeast and can irritate mucous membranes), propylene glycol (solvent/irritant), chlorhexidine in some formulations (broad-spectrum antimicrobial that disrupts mucosal microbiota): are absorbed through penile and scrotal skin. Scrotal skin has demonstrated high permeability for xenobiotics. The endocrine-disrupting potential of parabens in particular is well-documented from dermal absorption studies.

This is not a fringe concern. It is a simple question of where chemicals go when applied to permeable tissue. The assumption that "external" means "contained" has been disproved for countless products in the personal care literature. It applies here too.

Natural rubber latex (NRL) contains over 200 proteins, of which approximately 13 (Hev b proteins) have been identified as allergens. Two types of reactions occur:

Triggered by Hev b latex proteins. Onset within minutes of contact. Symptoms range from localized urticaria and swelling to systemic anaphylaxis. Systemic anaphylaxis from latex can be fatal. Cross-reactivity with banana, avocado, kiwi, chestnut, and passion fruit (latex-fruit syndrome) is well established: mediated by shared protein structures (class I chitinases). A person with a banana allergy should be screened for latex allergy before any latex exposure, including condoms.

Triggered not by latex proteins but by the chemical accelerators used in vulcanization: thiuram disulfides, carbamates (zinc dibutyldithiocarbamate), and mercaptobenzothiazole (MBT). These are processing chemicals that remain in the finished rubber product. Onset 12–48 hours after exposure. Symptoms: localized redness, blistering, itching at contact site. Many people attribute this to "latex allergy" when the actual trigger is accelerator chemicals. Relevant because polyisoprene condoms (marketed as latex-free) may use the same vulcanization chemicals.

Latex allergy rates have increased substantially since the 1980s. The most widely cited driver: universal precautions adoption following the HIV/AIDS epidemic resulted in dramatically increased use of latex gloves across healthcare settings. Sensitization in healthcare workers is estimated at 4–17%. General population rates range from 1–6% in studies, but sensitization in populations with high medical exposure is considerably higher. This matters for condom use: sensitization can occur through any repeated latex exposure and, once established, is permanent.

For women experiencing unexplained vaginal irritation, burning, or recurrent symptoms after intercourse with a latex condom, particularly when symptoms onset 12–48 hours post-exposure, a latex or chemical accelerator contact allergy should be investigated before any other workup.

Synthetic rubber. No natural latex proteins, Type I reactions not triggered. NOTE: may still contain vulcanization accelerators (thiurams/carbamates) that trigger Type IV contact dermatitis. Available in non-spermicidal formulations. Feel and stretch closer to latex than polyurethane.

No latex proteins. No vulcanization accelerators. Thinner than latex. Conducts heat well. Compatible with oil-based lubricants. Less elastic than latex, higher breakage rate reported in some studies. Carries STI protection.

The FC2 (female/internal condom) is made from nitrile: no latex, no latex proteins, no vulcanization accelerators. Pre-lubricated with a silicone-based lubricant. Controlled by the receiving partner. STI protection equivalent to male latex condom. Provides additional coverage of vaginal introitus.

Made from lamb cecum. No synthetic materials, no latex proteins, no processing chemicals. Effective for pregnancy prevention. DOES NOT protect against STIs. The natural pores in the membrane are too small for sperm but not for viruses (HIV, HSV, HPV). Appropriate for couples in monogamous relationships who are concerned about latex or synthetic chemical exposure.

Sustain (organic, non-N9, vegan), Glyde (certified vegan, no N9, no casein: some conventional condoms use casein in the powder), Hanx, Einhorn. Read the lubricant ingredients on any pre-lubricated condom. Look specifically for "nonoxynol-9" or "N-9." Unlubricated condoms with a separate clean lubricant (pure silicone or water-based without glycerin/parabens) give full control over what is applied.

The drug reference library on this site covers 12+ hormonal contraceptive entries in detail: side effects, nutrient depletions, excipients, withdrawal considerations, and body support. What follows is the clinical overview.

All combined estrogen-progestogen contraceptives are classified by the IARC as Group 1 human carcinogens, sufficient evidence of cancer causation. Cancers documented: breast, cervix, liver. This is the same classification as tobacco smoke and asbestos. It is not disclosed at the point of prescribing.

Synthetic progestins are metabolized through pathways that systematically deplete:

B6 (Pyridoxine)

Rate-limiting cofactor in serotonin and dopamine synthesis. B6 depletion is the direct mechanistic explanation for the documented depression with these drugs, not a side effect, a depletion consequence.

Required for skin integrity, ovulation, immune function, and testosterone production. Zinc depletion contributes to acne, immune vulnerability, and reduced libido on hormonal methods.

Magnesium

Intracellular depletion contributes to cramping, anxiety, and sleep disruption: all commonly reported on hormonal methods.

Folate (B9)

Critically depleted in women stopping hormonal contraception to conceive. Folate is essential for fetal neural tube development in the first weeks of pregnancy, before many women know they are pregnant.

Mitochondrial energy production. Depletion contributes to fatigue, one of the most common but least-acknowledged side effects of hormonal contraception.

Selenium + B2

Selenium is required for thyroid function and glutathione peroxidase. B2 (riboflavin) is required to convert B6 to its active form P5P, meaning B2 depletion amplifies the B6 depletion effect.

Depletion is not theoretical. The WHO's Advances in Fertility Regulation report documents that approximately 80% of women taking OCs have abnormal tryptophan metabolism, the biochemical signature of B6 deficiency. Peer-reviewed cross-sectional data put the prevalence of deficient or marginal plasma B6 at 40–48% of OC users, compared to 18% in non-users. Zinc and magnesium depletions are statistically significant (p<0.01 and p<0.05 respectively) and proportional to duration of use. OC use also elevates serum copper, which competes with zinc for absorption and amplifies the depletion. These are not rare adverse events. They are the predictable biochemical output of running synthetic hormones through pathways that depend on these cofactors.

The connection between the pill and depression is not mysterious. B6, in its active form pyridoxal 5'-phosphate (PLP), is the essential coenzyme for converting tryptophan into serotonin, and for producing dopamine and GABA. When B6 is depleted, tryptophan gets shunted through an alternate route: the kynurenine pathway. Estrogen-containing OCs specifically accelerate this shunting by increasing the activity of tryptophan oxygenase.

A 2023 study in Scientific Reports (Bjørke-Monsen et al., n=123) measured the metabolic consequences directly. Women on estrogen-containing OCs had significantly lower kynurenic acid, a neuroprotective metabolite, and significantly higher xanthurenic acid, an excitotoxic one. Their CRP (a systemic inflammation marker) was elevated and inversely associated with B6 and B2 status. The authors described the profile as one that "resembles the biochemical pattern observed in vitamin B6 deficiency." Women on progestin-only methods did not show this pattern, pointing specifically to the estrogen component.

A small but rigorous randomized crossover trial (Curtin & Johnston, Journal of Dietary Supplements, 2023) tested what happens when you correct the deficiency. Women aged 18–25 on combined OCs for at least one year were given 100 mg/day of B6 or placebo in alternating 4-week periods. Beck Depression Inventory scores fell by 20% with B6 supplementation and rose 11% with placebo, a statistically significant difference (p=0.046). The mechanism predicted the intervention. The intervention confirmed the mechanism.

The Skovlund 2016 Danish cohort, over one million women followed for a mean of 6.4 years, remains the most cited study. For all ages combined, combined OCs produced a 23% increased risk of first antidepressant prescription. For adolescents aged 15–19, the risk was 80%. For adolescents on progestin-only pills, it was 120%. For DMPA (Depo-Provera): 170%.

A 2023 population-based cohort from Uppsala (264,557 women) with sibling analysis (which controls for genetic and family-level confounding) found that women in their first two years of OC use had a 73% increased depression risk. For teenagers, the risk was 130%. The sibling methodology makes it harder to attribute the association to pre-existing vulnerability. The Uppsala cohort also documented something the earlier studies missed: adolescent OC users carried elevated depression risk even after stopping, a persistent effect not seen in adult users. Starting the pill young does not carry the same reversibility as starting it in adulthood.

Approximately 40% of the U.S. population carries at least one copy of the MTHFR C677T polymorphism, a genetic variant that reduces the enzyme converting dietary folate into its active, bioavailable form (5-methyltetrahydrofolate). Heterozygotes have roughly 40–60% reduced enzyme activity. Homozygotes (about 10–15% of the population) have up to 70% reduced activity. This matters clinically: active methylfolate is required to produce SAMe, which is the methyl donor for dopamine, serotonin, and norepinephrine synthesis. Women with C677T polymorphisms show a 36% increased odds of clinical depression in meta-analysis. Among patients with treatment-resistant major depression, 74–76% carry a positive MTHFR variant.

OC-induced folate depletion and MTHFR impairment compound each other. Standard folic acid supplementation does not bypass the block in C677T individuals. It requires the same impaired enzyme to become active. A teenager with an undetected MTHFR variant who starts the pill is experiencing reduced folate intake feeding into an already-compromised conversion pathway, pushing neurotransmitter synthesis failure. MTHFR status is not tested at contraceptive prescription. It is not mentioned. For women with OCP-coincident depression that does not resolve after stopping the pill or after SSRI trial, MTHFR genotyping is worth pursuing.

Estrogen-containing OCs stimulate hepatic production of thyroid binding globulin (TBG) through a specific mechanism: increased sialylation of TBG in the liver slows its clearance. The functional result, in a 200-woman study, was that 65% of euthyroid OC users had TBG levels exceeding the upper limit of normal. Total T4 rose a median of 24% (from 97 to 120 nmol/L). Total T3 in 16% of euthyroid OC users appeared falsely elevated into the hyperthyroid range, despite normal TSH and normal free T4.

In a woman with normal thyroid function, this doesn't produce a clinical problem. Free T4 and TSH remain accurate indicators of actual thyroid status. But in a woman on levothyroxine, OC use substantially increases her dose requirement because more TBG capacity binds her medication, reducing free T4. And in any OC user who gets total T3 or total T4 run as part of a lab panel, those results are unreliable without knowing that OC use elevates them. Free T4 and TSH are the only reliable thyroid markers in this population.

Oral contraceptives dramatically increase sex hormone binding globulin (SHBG), the protein that binds testosterone (and estrogen), rendering it biologically unavailable. Dr. Claudia Panzer's research (2006) showed that SHBG remained elevated in some women for months to years after stopping the pill, meaning that the libido suppression documented on OCs may not resolve when the pill is stopped. In some women, the SHBG elevation appears to persist long-term, reducing free testosterone chronically. This is one of the most under-recognized post-OC sequelae, particularly in women who started hormonal contraception in their teens.

Research by Claus Wedekind and colleagues (the "sweaty T-shirt" study and its replications) established that women, when not on hormonal contraception, are attracted to men with dissimilar major histocompatibility complex (MHC) genotypes. A biological signal for genetic complementarity and diverse immune function in offspring. Women on OCs show this preference reversed: they prefer MHC-similar men. A woman who begins or stops hormonal contraception while in a relationship may find her perception of her partner genuinely changes, not psychologically, but because the underlying olfactory/hormonal signaling system has shifted.

Ethinyl estradiol, the synthetic estrogen in most combined OCs, is excreted in urine and passes through standard municipal water treatment largely intact. Documented feminization of male fish in waterways downstream of wastewater treatment plants is a direct consequence of ethinyl estradiol in treated water. The implications for human male reproductive health from chronic low-level EE2 exposure through municipal water are being studied but are not resolved. It is an environmental contamination issue that originates at the individual prescription level.

The IUD category contains two fundamentally different mechanisms (one non-hormonal and one hormonal) that are often discussed as if they were variations of the same thing. They are not.

The Paragard is a T-shaped polyethylene frame wound with copper wire. It works because copper ions are toxic to sperm, copper drives oxidative stress in the uterine environment, impairing sperm motility and viability via reactive oxygen species generation. This is its mechanism. It is also the mechanism for its primary side effects.

Copper ions sustain a chronic low-grade inflammatory state in the endometrium. Heavier periods and significant cramping are direct biochemical consequences of this inflammation, not coincidental side effects. The same oxidative environment that destroys sperm also generates ROS in endometrial tissue. Women who are already iron-loaded or who have any tendency toward oxidative burden may find this device particularly difficult to tolerate.

The genuine advantages of the copper IUD are real: it is non-hormonal, highly effective (99%+), and immediately reversible. For women who cannot use hormonal methods for medical or personal reasons, the Paragard represents the most effective long-acting non-hormonal option available. The decision requires understanding both the mechanism and the downstream mineral physiology, which is not the conversation that happens at insertion.

Mirena releases 20mcg/day of levonorgestrel, a first-generation synthetic progestin from the 19-nortestosterone family. Kyleena releases 8mcg/day; Liletta 12mcg/day; Skyla 6mcg/day. These are presented as "localized" delivery with minimal systemic effects. The claim is partially true: systemic levonorgestrel levels from an IUD are lower than from the pill. The claim is not entirely true: levonorgestrel IS detectable in serum in women using LNG-IUDs, and systemic effects (including changes in libido, mood, acne, and SHBG) are documented and reported.

Levonorgestrel is androgenic. It was designed to bind progesterone receptors but has meaningful affinity for androgen receptors. Androgenic side effects (acne, mood changes, decreased libido, facial hair in sensitive women) are biologically expected and clinically observed. This is not a case of drug-brand exaggeration. It is documented receptor pharmacology.

The elimination of periods with Mirena is heavily marketed as a benefit. The same principle applies here as with OCs: the absence of a withdrawal bleed is not the same as natural amenorrhea. It is suppression of endometrial growth by continuous progestin exposure. The monthly cycle is a hormonal signal cascade involving the hypothalamic-pituitary-ovarian axis, the endometrium, and the immune system. The absence of that cycle removes the signal, not the underlying physiology. What the long-term effect of years of endometrial suppression is for individual women has not been adequately studied.

Mirena's hormone reservoir is a polydimethylsiloxane (silicone) capsule on the IUD frame. The T-frame is polyethylene. The device contains barium sulfate and iron oxide as radiopaque/ultrasound-visible markers. Insertion requires cervical dilation via tenaculum, the same procedure documented in the pap smear page, with associated perforation risk (0.1–0.3%) and expulsion risk (5–10% in the first year).

Depo-Provera delivers 150mg of medroxyprogesterone acetate (MPA), a synthetic progestin, in a depot injection lasting approximately 12 weeks. Once injected, the decision cannot be reversed. If you experience side effects at week two, you are committed to week twelve.

FDA Black Box Warning: Bone Density Loss (2004)

Depo-Provera causes a significant and potentially irreversible reduction in bone mineral density. The FDA mandated a Black Box Warning in 2004 stating that Depo-Provera should not be used for more than 2 years unless other birth control methods are inadequate. Bone density loss begins within the first year of use and may not fully recover after discontinuation, particularly in women who started use during adolescence, when peak bone mass is being established. This warning is not prominently disclosed at the point of prescription, and many women use it continuously for years beyond the 2-year threshold.

MPA is not bioidentical to progesterone. It has glucocorticoid activity (contributing to cortisol-like effects, including weight gain and mood disruption) and androgenic activity (contributing to acne and libido loss). These are structural pharmacological properties, not rare idiosyncratic reactions.

Return to fertility after stopping Depo-Provera is the most delayed of any reversible contraceptive method: average 10–18 months. For women who stop Depo intending to conceive, the fertility gap is clinically significant and is routinely underdisclosed.

The injectable formulation contains: polyethylene glycol 3350, polysorbate 80, methylparaben (a paraben preservative: injected intramuscularly with every dose), sodium chloride. These excipients are injected directly into muscle tissue with each quarterly dose.

The diaphragm, a dome-shaped silicone or latex cup inserted to cover the cervix, is a purely mechanical barrier with no systemic effects. Historically used with N-9 spermicide; the same concerns apply there as with condom-applied N-9. The Caya contoured diaphragm (FDA approved 2014) is silicone and is designed to be effective without spermicide, though efficacy is somewhat lower without it.

The cervical cap (FemCap) is a smaller silicone device that fits over the cervix and remains in place. Also traditionally used with spermicide. Less effective than the diaphragm in women who have given birth, because the cervix changes shape post-delivery.

Neither device has systemic effects. Neither disrupts the hormonal cycle. The diaphragm and cervical cap are the most clinically underused barrier methods in modern practice, not because they are ineffective, but because they require fitting by a provider and are not billable at the same rate as device insertion. For women seeking non-hormonal, non-copper options, the silicone diaphragm with a clean lubricant (no N-9) is one of the most physiologically inert contraceptive options available.

Contraceptive choice is individual, hormonal context is individual, and relationship circumstances are individual. None of this page is an argument for a specific choice. It is the information that belongs in the appointment and routinely isn't there.